+9 C°
Traffic jam:   6

Moderna is developing a two-in-one vaccine

11 September 2021
2 min.
Moderna is developing a two-in-one vaccine

2-in-1 vaccine

Moderna's shares have increased dramatically after the announcement of the development of a comprehensive booster vaccine that simultaneously protects against new strains of the COVID-19 virus and seasonal influenza strains, as well as studies on cancer vaccines.

Moderna shares are up 336.4% since the start of 2021 and more than 700% in the past 12 months. Moderna's main competitors in COVID-19 vaccine sales: Pfizer (PFE) and Johnson & Johnson (JNJ) shares were down 1% and 2.2% respectively at the close of trading on Thursday.

Novavax (NVAX), which has not yet received US approval for its COVID-19 vaccine, said it was also conducting a study to test a combination flu and COVID-19 vaccine.

The combined vaccine is being created because the World Health Organization (WHO) has said that it is likely that the COVID-19 virus will not be eradicated completely and people will need to be vaccinated annually against the coronavirus, as they are currently vaccinated against seasonal strains of influenza.

According to WHO officials, the virus has spread and mutated too widely, so the current programme of twice-daily vaccinations will not be enough to eradicate COVID-19.

At the same time, WHO has now imposed a moratorium on the use of repeat booster doses of Covid-19 vaccines until at least the end of the year.

The WHO justified this decision by the fact that "little has changed in the world situation" and it is necessary "for each country to be able to vaccinate at least 40% of its population at least until the end of the year".

Nevertheless, this measure is temporary and the world population does seem to be facing annual re-vaccination against these dangerous viral infections.

Moderna has seen an incredible increase in sales and profits from its COVID vaccines, which, according to research, build stronger and longer-lasting immunity in older people and have greater efficacy against the Delta strain than counterparts from Pfizer and BioNTech (BNTX).

Moderna said that it currently has: 37 programmes in development, including 22 in clinical trials.

Vaccine sales will generate steadily growing revenues and profits for Moderna and its shareholders.

Companies6 in the news

1 place
2 place
3 place
5 place


Rating companies
197 Mention
Dow Jones
140 Mention
77 Mention
66 Mention
65 Mention
59 Mention
45 Mention


News from GlobalNY.biz is the freshest and most relevant information about high-profile events in the region. The task of the resource's news feed is to convey to readers with maximum accuracy and objectivity information about important events in business, politics, economy, healthcare, culture and other spheres of life in New York.
GlobalNY.biz news is a coverage of economic processes taking place in New York, the latest news of public life, incidents and an overview of political events. New York news is information about the activities of small and medium-sized businesses, the work of housing and communal services and utilities, the implementation of significant projects.
The site's journalists describe not only the life of the region, but also talk about the current state of the US economy. Everything you need to know about innovations in the field of industry and agriculture, economy and power is collected in the "News" section at GlobalNY.biz.
New York news quickly informs the reader, shows the real picture and opens up hot topics. Communication with government structures and business enables us to provide our readers with reliable, information-rich material. The main page of the portal contains the key news of New York!
Alena Potapova

Development Director
Died this year
Born this year